UGT2B7
From Wikipedia, the free encyclopedia
| UDP glucuronosyltransferase 2 family, polypeptide B7 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 PDB rendering based on 2o6l. | |||||||||||||
| |||||||||||||
| Identifiers | |||||||||||||
| Symbols | UGT2B7; UDPGT 2B9; UDPGT2B7; UDPGTH2; UGT2B9 | ||||||||||||
| External IDs | OMIM: 600068 HomoloGene: 128251 ChEMBL: 4370 GeneCards: UGT2B7 Gene | ||||||||||||
| EC number | 2.4.1.17 | ||||||||||||
| |||||||||||||
| Orthologs | |||||||||||||
| Species | Human | Mouse | |||||||||||
| Entrez | 7364 | 231396 | |||||||||||
| Ensembl | ENSG00000171234 | ENSMUSG00000070704 | |||||||||||
| UniProt | P16662 | n/a | |||||||||||
| RefSeq (mRNA) | NM_001074 | NM_001029867 | |||||||||||
| RefSeq (protein) | NP_001065 | NP_001025038 | |||||||||||
| Location (UCSC) | Chr 4: 69.92 – 69.98 Mb | Chr 5: 87.07 – 87.09 Mb | |||||||||||
| PubMed search | |||||||||||||
UGT2B7 (UDP-Glucuronosyltransferase-2B7) is a phase II metabolism isoenzyme found to be active in the liver, kidneys, epithelial cells of the lower gastrointestinal tract and also has been reported in the brain. In humans, UDP-Glucuronosyltransferase-2B7 is encoded by the UGT2B7 gene.[1][2]
Function
The UGTs serve a major role in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. UGT2B7 has unique specificity for 3,4-catechol estrogens and estriol, suggesting that it may play an important role in regulating the level and activity of these potent estrogen metabolites.
This enzyme is located on the endoplasmic reticulum and nuclear membranes of cells. Its function is to catalyse the conjugation of a wide variety of lipophilic aglycon substrates with glucuronic acid, using uridine diphosphate glucuronic acid.
Together with UGT2B4, UGT2B7 is capable of glucosidation of hyodesoxycholic acid in the liver, but, unlike the 2B4 isoform, 2B7 is also able to glucuronidate various steroid hormones (androsterone, epitestosterone) and fatty acids.[3][4] It is also able to conjugate major classes of drugs such as analgesics (morphine), carboxylic nonsteroidal anti-inflammatory drugs (ketoprofen), and anticarcinogens (all-trans retinoic acid).[4] UGT2B7 is the major enzyme isoform for the metabolism of morphine to the main metabolites, morphine-3-glucuronide (M3G) which has no analgesic effect and morphine-6-glucuronide (M6G),[5] which has analgesic effects less potent than morphine.[6] As a consequence, altered UGT2B7 activity can significantly affect both the effectiveness and side-effects of morphine, as well as some related opiate drugs.[7][8][9][10][11]
References
- ↑ Ritter JK, Sheen YY, Owens IS (May 1990). "Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells. 3,4-catechol estrogens and estriol as primary substrates". J. Biol. Chem. 265 (14): 7900–6. PMID 2159463.
- ↑ Monaghan G, Clarke DJ, Povey S, See CG, Boxer M, Burchell B (September 1994). "Isolation of a human YAC contig encompassing a cluster of UGT2 genes and its regional localization to chromosome 4q13". Genomics 23 (2): 496–9. doi:10.1006/geno.1994.1531. PMID 7835904.
- ↑ Mackenzie P, Little JM, Radominska-Pandya A (February 2003). "Glucosidation of hyodeoxycholic acid by UDP-glucuronosyltransferase 2B7". Biochem. Pharmacol. 65 (3): 417–21. doi:10.1016/S0006-2952(02)01522-8. PMID 12527334.
- ↑ 4.0 4.1 Barre L, Fournel-Gigleux S, Finel M, Netter P, Magdalou J, Ouzzine M (March 2007). "Substrate specificity of the human UDP-glucuronosyltransferase UGT2B4 and UGT2B7. Identification of a critical aromatic amino acid residue at position 33". FEBS J. 274 (5): 1256–64. doi:10.1111/j.1742-4658.2007.05670.x. PMID 17263731.
- ↑ Coffman B, Rios G, King C, Tephly T (1 January 1997). "Human UGT2B7 catalyzes morphine glucuronidation". Drug Metab. Dispos. 25 (1): 1–4. PMID 9010622.
- ↑ van Dorp EL, Romberg R, Sarton E, Bovill JG, Dahan A (2006). "Morphine-6-glucuronide: morphine's successor for postoperative pain relief?". Anesthesia and Analgesia 102 (6): 1789–1797. doi:10.1213/01.ane.0000217197.96784.c3. PMID 16717327.
- ↑ Coller, JK; Christrup, LL; Somogyi, AA (2009). "Role of active metabolites in the use of opioids.". European journal of clinical pharmacology 65 (2): 121–39. doi:10.1007/s00228-008-0570-y. PMID 18958460.
- ↑ Fujita, KI; Ando, Y; Yamamoto, W; Miya, T; Endo, H; Sunakawa, Y; Araki, K; Kodama, K; Nagashima, F (2009). "Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer". Cancer chemotherapy and pharmacology 65 (2): 251–8. doi:10.1007/s00280-009-1029-2. PMID 19466410.
- ↑ Abildskov, K; Weldy, P; Garland, M (2010). "Molecular Cloning of the Baboon UDP-Glucuronosyltransferase 2B Gene Family and Their Activity in Conjugating Morphine". Drug metabolism and disposition: the biological fate of chemicals 38 (4): 545–53. doi:10.1124/dmd.109.030635. PMC 2845934. PMID 20071451.
- ↑ Pergolizzi, JV; Raffa, RB; Gould, E (2009). "Considerations on the use of oxymorphone in geriatric patients". Expert opinion on drug safety 8 (5): 603–13. doi:10.1517/14740330903153854. PMID 19614559.
- ↑ Rouguieg, K; Picard, N; Sauvage, FL; Gaulier, JM; Marquet, P (2010). "Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes". Drug metabolism and disposition: the biological fate of chemicals 38 (1): 40–5. doi:10.1124/dmd.109.029546. PMID 19841060.
Further reading
- Kwara A; Lartey M; Boamah I et al. (2009). "Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV Co-infected Ghanaian Patients: UGT2B7*1C is Associated with Faster Zidovudine Clearance and Glucuronidation". J Clin Pharmacol 49 (9): 1079–90. doi:10.1177/0091270009338482. PMC 2749505. PMID 19628728.
- Canzian F; Cox DG; Setiawan VW et al. (2010). "Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium". Hum. Mol. Genet. 19 (19): 3873–84. doi:10.1093/hmg/ddq291. PMC 2935856. PMID 20634197.
- Hwang MS; Lee SJ; Jeong HE et al. (2010). "Genetic variations in UDP-glucuronosyltransferase 2B7 gene (UGT2B7) in a Korean population". Drug Metab. Pharmacokinet. 25 (4): 398–402. doi:10.2133/dmpk.DMPK-10-SC-021. PMID 20814162.
- Rose JE; Behm FM; Drgon T et al. (2010). "Personalized Smoking Cessation: Interactions between Nicotine Dose, Dependence and Quit-Success Genotype Score". Mol. Med. 16 (7–8): 247–53. doi:10.2119/molmed.2009.00159. PMC 2896464. PMID 20379614.
- Holmes MV; Shah T; Vickery C et al. (2009). "Fulfilling the Promise of Personalized Medicine? Systematic Review and Field Synopsis of Pharmacogenetic Studies". In Luo, Yuan. PLoS ONE 4 (12): e7960. doi:10.1371/journal.pone.0007960. PMC 2778625. PMID 19956635.
- Kwara A; Lartey M; Sagoe KW et al. (2009). "CYP2B6, CYP2A6 and UGT2B7 Genetic Polymorphisms are Predictors of Efavirenz Mid-dose Concentration in HIV-infected Patients". AIDS 23 (16): 2101–6. doi:10.1097/QAD.0b013e3283319908. PMC 2875867. PMID 19779319.
- Setlur SR; Chen CX; Hossain RR et al. (2010). "Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer". Cancer Epidemiol. Biomarkers Prev. 19 (1): 229–39. doi:10.1158/1055-9965.EPI-09-1018. PMID 20056642.
- Sánchez MB; Herranz JL; Leno C et al. (2010). "Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy". Seizure 19 (2): 93–101. doi:10.1016/j.seizure.2009.12.004. PMID 20064729.
- Chen M; LeDuc B; Kerr S et al. (2010). "Identification of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol". Drug Metab. Dispos. 38 (3): 368–75. doi:10.1124/dmd.109.029900. PMID 20008037.
- Ross CJ; Katzov-Eckert H; Dubé MP et al. (2009). "Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy". Nat. Genet. 41 (12): 1345–9. doi:10.1038/ng.478. PMID 19898482.
- Tang L; Ye L; Singh R et al. (2010). "Use of Glucuronidation Fingerprinting to Describe and Predict mono- and di-Hydroxyflavone Metabolism by Recombinant UGT Isoforms and Human Intestinal and Liver Microsomes". Mol. Pharm. 7 (3): 664–79. doi:10.1021/mp900223c. PMC 2941766. PMID 20297805.
- Woillard JB; Rerolle JP; Picard N et al. (2010). "Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8*2 variant allele". Br J Clin Pharmacol 69 (6): 675–83. doi:10.1111/j.1365-2125.2010.03625.x. PMC 2883760. PMID 20565459.
- Yu L; Qian M; Liu Y et al. (2010). "Stereoselective metabolism of propranolol glucuronidation by human UDP-glucuronosyltransferases 2B7 and 1A9". Chirality 22 (4): 456–61. doi:10.1002/chir.20765. PMID 19644937.
- Yang JW; Lee PH; Hutchinson IV et al. (2009). "Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid". Ther Drug Monit 31 (5): 542–8. doi:10.1097/FTD.0b013e3181b1dd5e. PMID 19730281.
- Ahn J; Schumacher FR; Berndt SI et al. (2009). "Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3)". Hum. Mol. Genet. 18 (19): 3749–57. doi:10.1093/hmg/ddp302. PMC 2742399. PMID 19574343.
- Hu M; Lui SS; Mak VW et al. (2010). "Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients". Pharmacogenet. Genomics 20 (10): 634–7. doi:10.1097/FPC.0b013e32833de489. PMID 20679960.
- Zhao W; Fakhoury M; Deschênes G et al. (2010). "Population Pharmacokinetics and Pharmacogenetics of Mycophenolic Acid Following Administration of Mycophenolate Mofetil in De Novo Pediatric Renal-Transplant Patients". Journal of clinical pharmacology 50 (11): 1280–91. doi:10.1177/0091270009357429. PMID 20147615.
- Blanca Sánchez M; Herranz; Leno C et al. (2010). "UGT2B7_-161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study". Ther Drug Monit 32 (2): 177–84. doi:10.1097/FTD.0b013e3181ceecc6. PMID 20216122.
- Yong M; Schwartz SM; Atkinson C et al. (2010). "Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States". Cancer Epidemiol. Biomarkers Prev. 19 (2): 537–46. doi:10.1158/1055-9965.EPI-09-0898. PMC 2820123. PMID 20142249.
- Joy MS; Boyette T; Hu Y et al. (2010). "Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis". European journal of clinical pharmacology 66 (11): 1119–30. doi:10.1007/s00228-010-0846-x. PMID 20567810.
External links
- human UGT2B7 at the US National Library of Medicine Medical Subject Headings (MeSH)
- UGT2B7 protein, human at the US National Library of Medicine Medical Subject Headings (MeSH)
- "GT2B7". PharmGKB. PharmGKB. Retrieved 2009-01-13.
| ||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.